Development
Emergent BioSolutions Inc.
EBS
$6.22
-$0.02-0.32%
NYSE
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | -259.40% | -1,840.49% | -717.41% | -348.19% | -191.64% |
| Total Depreciation and Amortization | -4.21% | -13.38% | 8.67% | 6.59% | 5.49% |
| Total Amortization of Deferred Charges | 419.51% | 304.88% | 192.68% | 0.00% | 0.00% |
| Total Other Non-Cash Items | 964.81% | 577.07% | 84.25% | -72.76% | -62.17% |
| Change in Net Operating Assets | -3,247.62% | 197.19% | -21.23% | 131.08% | 98.66% |
| Cash from Operations | -504.99% | -172.04% | -195.49% | -164.87% | -110.62% |
| Capital Expenditure | 55.44% | 54.07% | 52.41% | 50.92% | 48.53% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 97.63% | 88.47% | -- | -- | -- |
| Cash from Investing | 155.68% | 146.60% | 55.23% | -81.10% | -69.47% |
| Total Debt Issued | -96.66% | 51.26% | -- | -- | -- |
| Total Debt Repaid | -1,566.86% | -1,549.85% | -1,587.70% | -19.50% | 5.85% |
| Issuance of Common Stock | 104.00% | 79.69% | 29.21% | -52.63% | -68.55% |
| Repurchase of Common Stock | 97.16% | 98.56% | 98.45% | 83.77% | 26.54% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -211.33% | -1,134.81% | 139.32% | 385.90% | 441.28% |
| Foreign Exchange rate Adjustments | -340.00% | 333.33% | -450.00% | 300.00% | 266.67% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -900.75% | 6.01% | -201.68% | 94.82% | 246.68% |